Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
A Phase 3, Randomized, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 in Healthy Infants Given in a 2-, 3-, 4-, and 12-Month Schedule With Routine Pediatric Vaccinations
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Listed as NCT00366548, this PHASE3 trial focuses on Vaccines, Pneumococcal and remains completed. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bydgoszcz, Poland , Dębica, Poland , Krakow, Poland , Lodz, Poland , Lubartów, Poland , Lublin, Poland , Oborniki Śląskie, Poland , Poznan, Poland , Siemianowice Śląskie, Poland , Torun, Poland and 1 more location